3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Prostatic Neoplasms
2
Weight Loss
1
Urinary Bladder Neoplasms
1
Sleep Apnea Syndromes
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Overweight
1
Obesity, Morbid
1
Obesity
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Hypertension
1
Hyperlipidemias
1
Gastroesophageal Reflux
1
Eczema
1
Disease
1
Digestive System Diseases
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Dermatitis, Atopic
1
Collagen Diseases
1
Adenocarcinoma
1
Interventions
Gemcitabine
56
pembrolizumab
50
Cisplatin
43
Magnetic Resonance Spectroscopy
27
enfortumab vedotin
22
Specimen Handling
22
Nivolumab
22
Cystectomy
18
durvalumab
16
Carboplatin
16
avelumab
15
Mitomycin
14
atezolizumab
13
Docetaxel
13
Cystoscopy
12
Fluorouracil
11
Radiation
9
Transurethral Resection of Bladder
8
Radiotherapy
8
Ipilimumab
8
sacituzumab govitecan
7
Standard of Care
7
Radiosurgery
7
Paclitaxel
7
Immunoglobulin G
7
Disulfides
7
erdafitinib
6
cemiplimab
6
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Urine Specimen Collection
×
1 year
×
Clear all
NCT05151341
2025-07-24
URODX-FGFR3
Institut de Cancérologie de Lorraine
Phase NA
Completed
190 enrolled